Publication date: September 3, 2025
Fresenius Medical Care is a global leader in dialysis products and services and plays a crucial role in healthcare for patients with chronic kidney disease. The company combines the production of high-quality medical equipment with a large network of dialysis clinics. In this article, you can read all about Fresenius Medical Care shares: share price, performance, business strategy and expectations for 2025. Would you like to receive weekly updates on European stocks? Then subscribe to our newsletter here and stay informed.
image_here
- Year of establishment: 1996
- Year added to the DAX 40: 2024 (reinstated)
-Highest price ever: €93.82 February 2018
- Average trading volume: 551,460 thousand shares per day
- Share price performance over the past 12 months: +20.22%
Introduction about the company
Fresenius Medical Care AG & Co. KGaA is a German-American company headquartered in Bad Homburg, Hesse. The company was formed in 1996 from a merger between Fresenius AG and U.S.-based National Medical Care. Since then, it has grown to become the world's largest provider of dialysis products and services. Fresenius Medical Care develops and manufactures dialysis machines, dialysis filters and related medical supplies and also operates more than 4,000 dialysis clinics worldwide.
Key figures & achievements
In 2024, Fresenius Medical Care realized a turnover of over €19.33 billion and a net profit of €1.05 billion. This confirms the group's leading position in the dialysis sector. The market capitalization in July 2025 was approximately €13 billion, while the share price showed a solid increase of over 20% over the past 12 months.
History & development
Fresenius Medical Care was founded in 1996 through the merger of the dialysis businesses of Fresenius AG and National Medical Care. This merger created a global player that controlled both production and medical services. Over the years, the company expanded its global network of clinics, especially in North America, Europe and Asia. Since its inclusion in the DAX 40 in 2024, the group reaffirms its status as one of the leading healthcare companies in Germany.
Sector & competition
Fresenius Medical Care operates in the global healthcare market, with a clear focus on kidney dialysis. The sector is characterized by structural demand growth caused by the increase in chronic kidney diseases worldwide. At the same time, margins are under pressure due to rising healthcare costs and strict regulations. Major competitors include DaVita and B. Braun. However, Fresenius Medical Care's unique integrated model, equipment manufacturing and clinic operations provide the company with economies of scale and recurring revenues.
cta_here
Influence of Fresenius Medical Care on the DAX 40
With a weighting of approximately 0.97% (measured in December 2024) within the DAX 40, Fresenius Medical Care occupies a stable but modest position in the index. Movements in the share price have a limited impact on the overall performance of the DAX, but are an important indicator of the performance of the European healthcare sector. The stock price reacts strongly to developments in regulations, healthcare budgets and global demand for dialysis treatments. View the composition of the DAX 40 and the weighting of all companies in the DAX 40 here.
Investment analysis & outlook
Fresenius Medical Care shares showed a recovery over the past 12 months with a price increase of over 20%. With this, the company managed to give investors renewed confidence after several difficult years in which cost increases and pressure on margins negatively affected earnings. The integrated business model, with both production of dialysis equipment and operation of clinics, ensures stable revenues and provides a strong foundation for future growth.
However, the attached chart makes it clear that Fresenius Medical Care has lagged significantly behind the broader DAX in recent years. While the index has risen more than 80% since 2020, the stock is still down more than 40%. This highlights the challenges the company faces, but also shows that there is room for catching up if the strategy around cost control, digitalization and expansion into growth markets is successfully implemented.
Looking ahead, Fresenius Medical Care is focusing on further expanding its clinic network in Asia and investing in digital care solutions and new dialysis technologies. For investors looking for stability in healthcare and believing in recovery potential, the stock remains an interesting but challenging choice within the DAX 40.
News & updates
2025, Fresenius Medical Care announced the continued expansion of its clinic network in Asia, with new sites in India and China. It is also investing in digital platforms for patient care, enabling treatments to be carried out more efficiently and patient-friendly. The company also confirmed its sustainability goals to significantly reduce carbon emissions per dialysis treatment by 2030.
Disclaimer: Investing involves risk. Our analysts are not financial advisors. Always consult an advisor when making financial decisions. The information and tips provided on this website are based on our analysts' own insights and experiences. They are therefore for educational purposes only.